Table 1. Distribution of patients by tumor localization and schedule treatment.
| Nimotuzumab (mg/week) | 100 | 200 | 250 | 300 | 400 | 500 | 600 | Total (%) |
|---|---|---|---|---|---|---|---|---|
| n (%) | 6 (2.9) | 47 (22.9) | 1 (0.5) | 12 (5.9) | 130 (63.4) | 1 (0.5) | 8 (3.9) | 205 (100) |
| NSCLC | 0 | 5 | 0 | 2 | 16 | 0 | 0 | 23 (11.2) |
| ESOC | 0 | 11 | 0 | 1 | 8 | 0 | 1 | 21 (10.2) |
| CRC | 0 | 12 | 1 | 6 | 48 | 1 | 3 | 71 (34.6) |
| H&NC | 2 | 11 | 0 | 1 | 18 | 0 | 2 | 34 (16.6) |
| GC | 3 | 3 | 0 | 1 | 27 | 0 | 1 | 35 (17.1) |
| Others | 1 | 5 | 0 | 1 | 13 | 0 | 1 | 21 (10.3) |
NSCLC: non small cell lung cancer; ESOC: esophageal cancer; H&NC: head and neck cancer; CRC: colorectal cancer; GC: gastric cancer.